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Abstract: New strategies are continuously sought for the treatment of skin and wound infections
due to increased problems with non-healing wounds. Electrospun nanofiber mats with antibacterial
agents as drug delivery systems provide opportunities for the eradication of bacterial infections
as well as wound healing. Antibacterial activities of such mats are directly linked with their
drug release behavior. Traditional pharmacopoeial drug release testing settings are not always
suitable for analyzing the release behavior of fiber mats intended for the local drug delivery.
We tested and compared different drug release model systems for the previously characterized
electrospun chloramphenicol (CAM)-loaded nanofiber (polycaprolactone (PCL)) and microfiber (PCL
in combination with polyethylene oxide) mats with different drug release profiles. Drug release
into buffer solution and hydrogel was investigated and drug concentration was determined using
either high-performance liquid chromatography, ultraviolet-visible spectrophotometry, or ultraviolet
(UV) imaging. The CAM release and its antibacterial effects in disc diffusion assay were assessed by
bacterial bioreporters. All tested model systems enabled to study the drug release from electrospun
mats. It was found that the release into buffer solution showed larger differences in the drug release
rate between differently designed mats compared to the hydrogel release tests. The UV imaging
method provided an insight into the interactions with an agarose hydrogel mimicking wound tissue,
thus giving us information about early drug release from the mat. Bacterial bioreporters showed
clear correlations between the drug release into gel and antibacterial activity of the electrospun
CAM-loaded mats.
Keywords: antibacterial activity; bacterial bioreporters; drug release; electrospinning; microfibers;
nanofibers; UV imaging
1. Introduction
Electrospinning is a highly versatile and robust technique that allows production of fibers with
diameters from several nanometers to tens of micrometers [1]. Drug-loaded electrospun nanofiber
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mats have been studied intensively and show potential as drug delivery systems (DDSs) [2] and tissue
engineering scaffolds [3,4] due to several advantages, such as huge specific surface area, porosity
and the possibility to modify the drug release kinetics [5–7]. Compared to other delivery systems,
nano- and microfiber mats enable control and tuning of the drug release kinetics [8] and, hence, design
the mats with desired properties [9,10]. For example, for local antibiotic delivery, the desired drug
release needs to follow two steps: initial fast release followed by the slow zero-order kinetics over a
longer period of time [11]. Novel strategies for attaining sustained release have been proposed, for
example via the formation of core-shell structures [12,13], beads [14], or modification of nanofiber mat
thickness [15]. The drug release process is affected by several factors, such as the physicochemical
properties of the drug and carrier polymer, the structural characteristics of the material system, release
environment, and the possible interactions between these factors [16]. It is known that drug release
from electrospun fiber mats may vary depending on the material properties and the structure of the
mats [9,15,17,18].
Despite the substantial body of literature on electrospun fiber mats and their characterization, there
is no standard method for the analysis of drug release from fiber mats. Traditional pharmacopoeial
drug dissolution tests have been found useful for the analysis of nanofibers incorporated into capsules
or pressed into a tablet [19,20]. However, when electrospun nanofiber mats are intended for the
local delivery of drug, e.g., wound therapy, the amount of available liquid is low. Thus, mimicking
the actual biorelevant conditions in vitro may be challenging using standardized dissolution testing
conditions. Researchers have used methods where the amount of dissolution medium is much reduced
and size of the sample is close to the actual size of the nanofiber mat used in vivo [18,21–23]. Samples
are typically collected at predetermined time intervals and analyzed by ultraviolet-visible (UV-VIS)
spectrophotometry or high performance liquid chromatography (HPLC).
The biorelevant conditions applied for the drug release studies depend on the exact problem and
site of application, and may vary. Hydrogels have been widely used as DDSs for topical applications;
however, hydrogels may also provide for a simplistic wound model onto which drug may be released
followed by drug diffusion into the hydrogel matrix. Diffusion is one of the major transport mechanisms
in the wound [16,24], although swelling and erosion may also play a role depending on the formulation.
For some electrospun nanofibers, the release rate has also been explained by desorption of the embedded
drug from nanopores in the fibers or from the outer surface of the fibers in contact with the water
bath [25]. In addition to the actual testing, simulations have been performed and models proposed
that enable prediction of the drug release behavior of the electrospun fiber mats [16,26]. These models
enable the design of mats with certain structures in order to achieve a desired drug release kinetics [12].
Recently, a fully automated fiber-optics based dissolution testing systems for in situ monitoring of
drug release from electrospun fiber mats was proposed [27]. The direct ultraviolet (UV) measurement
of dissolved drug within dissolution medium provided the dissolution profile in real-time. UV imaging
technology has emerged in pharmaceutical analysis [28]. It has found use for the characterization
of different pharmaceutical dosage forms, including monitoring drug release from capsules [29],
patches [30], and hydrogels [31,32]. Spatially resolved absorbance values are measured facilitating
monitoring of concentrations and concentration gradients by UV imaging, and thereby providing the
potential for new insights to the drug dissolution and release processes through real-time monitoring
of swelling, precipitation, diffusion, and partitioning phenomena [31,33,34]. Drug release from
electrospun fiber mats into hydrogel system has not been investigated before and was of interest within
the present study.
In addition to using physical methods in drug release studies, genetically engineered whole-cell
bioreporters enable to obtain valuable information during drug release studies. A few of the main
advantages of using bioreporters are that they provide physiologically relevant data by measuring only
biologically available fraction of the chemical. A typical bioreporter consists of a biological recognition
element (i.e., sensor), a transducer, and a reporter protein. Test chemical binds to the sensor element, a
transducer initiates the production of the reporter protein, and a signal is produced [35,36]. In parallel
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to the drug release information, such methods give direct information about the bioactivity of the
developed antimicrobial DDSs.
The aim of the current study was to test and compare different drug release model systems for the
characterization of electrospun nano- and microfiber antibacterial drug-loaded mats. We studied two
different polymeric compositions—polycaprolactone (PCL) alone or in combination with polyethylene
oxide (PEO)—with the model antibacterial drug chloramphenicol (CAM). Interestingly, we have
previously shown that although these fiber mats with different carrier polymers have different drug
release behavior according to the dissolution test results, their antibacterial activity was rather similar in
a disc diffusion assay [22]. Therefore, in order to understand drug release from electrospun polymeric
fiber mats better, novel characterization methods were acquired in order to elucidate and rationalize
drug release behavior. In the current study, the drug release from electrospun fiber mats into buffer
solution and agar hydrogel was investigated using HPLC, UV-VIS spectrophotometry, and bacterial
bioreporters responding to the antibacterial drug CAM. UV imaging was used for the first time to
monitor real-time the drug release and diffusion from electrospun fiber mats into agarose hydrogel.
Antibacterial activity testing of the CAM containing fiber mats was performed using disc diffusion
assay in order to shed light on the correlation between the drug release and antibacterial activity and,
hence, the intended use of electrospun mats as local antibacterial DDSs for wound infections.
2. Materials and Methods
2.1. Materials, Bacteria and Release Media
Drugs, polymers, supplies. The antibacterial agent chloramphenicol (CAM) was used as a model
active pharmaceutical ingredient. CAM, hydrophobic carrier polymer polycaprolactone (PCL, Mw ≈
80,000), hydrophilic carrier polymer polyethylene oxide (PEO) (Mw ≈ 900,000), and all analytical grade
reagents were purchased from Sigma-Aldrich Inc. (Darmstadt, Germany). Ampicillin sodium salt
and anhydrous d-glucose used for the bacterial bioreporter preparation were obtained from Carl Roth
GmbH + Co. (Karsruhe, Germany) and Fisher Scientific (Waltham, MA, USA), respectively. Type I
agarose was purchased from Sigma-Aldrich (St. Louis, MO, USA). Agar hydrogel was prepared using
Lennox lysogeny broth (LB) agar (Difco Laboratories, Detroit, MI, USA). FavorPrep Plasmid DNA
Extraction Mini Kit and FavorPrep(TM) GEL/PCR Purification Mini Kit was purchased from Favorgen
Biotech Corp. (Changzhi Township, Pingtung, Taiwan).
Bacteria. Bacteria (Staphylococcus aureus DSM No.: 2569) were obtained from Leibniz Institute
DSMZ-German Collection of Microorganisms and Cell Cultures. Escherichia coli MG1655 strain [37]
was used for biosensor construction. Cloning was performed in E. coli strain DH5α [38].
Buffers and agarose hydrogel for drug release testing by UV imaging. For the preparation of the
phosphate buffer solution used as a dissolution medium, sodium dihydrogen phosphate dihydrate
(NaH2PO4 · 2H2O, Merck, Darmstadt, Germany) was dissolved in distilled water. The pH of the
solution (67 mM phosphate buffer) was adjusted to pH 7.40 using 5M sodium hydroxide solution.
The 0.5% (w/V) agarose hydrogel was prepared by dissolving type I agarose in an appropriate volume
of phosphate buffer kept at 98 ◦C for 45 min in a water bath. The gels were cast in the quartz cells,
and allowed to settle for 30 min prior to commencing the release experiments.
Buffers and agar hydrogels for drug release and antibacterial activity testing. Drug release studies
were conducted using phosphate buffered saline (1x PBS). Lennox lysogeny broth (LB) agar with a
concentration of 1.5% (w/V) (S. aureous) and MOPS minimal medium [39] with 1.5% (w/V) agar (E. coli)
were used for drug diffusion and antibacterial activity testing with bacteria.
2.2. Preparation and Characterization Methods
Preparation of electrospinning solutions and fiber mats. Fiber mats were prepared using an ESR200RD
robotized electrospinning system (NanoNC, Seoul, Republic of Korea). Fiber mats with different
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compositions were prepared in order to provide different drug release kinetics. The exact compositions
of the solutions used for electrospinning and electrospinning conditions are shown in Table 1.
Table 1. Composition of the electrospun formulations and electrospinning parameters.
Formulations Materials/Polymer Materials/Solvent Distance(cm)
Flow Rate
(ml/h)
Applied
Voltage (kV)
PCL PCL 12.5% (w/V),CONTROL
Chloroform:methanol
(3:1 V/V) 14 1.0 9
PCL/CAM PCL 12.5% (w/V) + CAM(4% w/w, solid state)
Chloroform:methanol
(3:1 V/V) 14 1.0 9
PCL/PEO PCL 10% + PEO 2% (w/V),CONTROL
Chloroform:methanol
(3:1 V/V) 17 2.5 12
PCL/PEO/CAM
PCL 10% (w/V) + PEO 2%
(w/V) + CAM (4% w/w,
solid state)
Chloroform:methanol
(3:1 V/V) 17 2.5 12
Key: CAM, chloramphenicol; CONTROL, formulation without CAM; PCL, polycaprolactone; PEO,
polyethylene oxide.
A mixture of chloroform:methanol (3:1) (V/V) was used as a solvent system for the preparation
of PCL and PCL/PEO systems, and a total of 10 mL was electrospun using rotation (20 rpm) and
moving stage (speed 25 mm/min, distance 140 mm). For the preparation of the electrospinning
solution, the polymers were dissolved in the solvent system under stirring overnight. The desired
CAM concentration in the fibers was 4% (dry solid state %) and CAM was added together with the
polymer into the solvent system immediately after the preparation. The electrospun fiber mats were
collected onto aluminum foil and put into ziploc bags. The samples were kept in a desiccator at 0%
relative humidity above silica gel to avoid humidity induced changes in the mats.
Morphology and solid state characterization of electrospun fiber mats. Morphology and diameter of
electrospun fiber mats were investigated using scanning electron microscopy (SEM). Samples were
mounted on aluminum stubs and magnetron-sputter coated with 3 nm gold layer in argon atmosphere
prior to microscopy. Solid state characterization of the electrospun fiber mats and drug-loaded fiber
mats was performed as described previously using attenuated total reflection-Fourier transform
infrared (ATR-FTIR) spectroscopy (IRPrestige-21 spectrophotometer (Shimadzu Corp., Kyoto, Japan)
with Specac Golden Gate Single Reflection ATR crystal (Specac Ltd., Orpington, UK) and verified with
X-ray diffraction (XRD) (D8 Advance, Bruker AXS GmbH, Karlsruhe, Germany) [22]. The thickness of
the fiber mats was verified using a Precision-Micrometer 533.501 (Scala Messzeuge GmbH, Dettingen,
Germany) with the resolution of 0.01 mm. The thickness of the mats was 0.07 ± 0.01 mm for the PCL
fiber (0.05 ± 0.01 mm with CAM) and 0.08 ± 0.01 mm for the PCL/PEO fiber (0.08 ± 0.01 mm with
CAM) mats.
Drug loading and distribution in fiber mats. High performance liquid chromatography (HPLC)
(Shimadzu Prominence HPLC with LC20, PDA detector SPD-M2QA, controlled by LC Solution software
(1.21 SP1 Shimadzu); Shimadzu Europa GmbH, Duisburg, Germany) was used to determine the CAM
concentration in the electrospun fiber mats and to evaluate its distribution uniformity throughout the
fiber mats. Analyses were performed according to the official European Pharmacopoeia method for
a related substance CAM sodium succinate. Briefly, CAM-loaded fiber samples were cut into 1 cm2
pieces, weighed, and dissolved in chloroform and methanol (3:1 V/V). The HPLC measurements were
performed using an octadecylsilyl column (Phenomenex, Luna C18(2), 250 × 4.6 mm, 5 µm). The flow
rate was 1.0 mL/min, and injection volume was 20 µL. The mobile phase consisted of 2% phosphoric
acid R, methanol R and water R in the volume ratio 5:40:55. A wavelength of 275 nm was used.
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2.3. Drug Release Studies
2.3.1. Drug Release Testing into Buffer Solution and Agar Hydrogel by UV-VIS Spectrophotometry
and HPLC
Drug release to buffer solution and agar hydrogel was investigated using UV-VIS
spectrophotometry and HPLC, respectively.
Release to phosphate buffer solution: The in vitro drug release of CAM from electrospun PCL and
PCL/PEO fiber mats was carried out as described previously [22]; however, a more frequent sampling
protocol was used. Briefly, 4 cm2 samples (N = 3) cut from the mats were weighed and placed into
20 mL of 1× PBS (pH 7.4) at 37 ◦C in 50 mL plastic tubes. The tubes were put into a dissolution
apparatus vessel (Dissolution system 2100, Distek Inc., North Brunswick, NJ, USA) containing water
maintained at 37 ◦C using rotation (paddle system, 100 rpm). Aliquots of 2 mL were removed and
replaced with the same amount of 1× PBS at set time points. The aliquots were analyzed using
UV-spectrophotometry (Shimadzu UV-1800, Shimadzu Europa GmbH, Duisburg, Germany) at 278 nm.
Release to agar hydrogel: The amount of drug released into agar plates was investigated by sampling
different zones of the agar (illustrated with a figure in Section 3.4). Pieces of fiber mat (PCL/CAM and
PCL/PEO/CAM fiber mat discs, with a diameter of 1 cm) were weighed, put onto pre-warmed LB agar
plates, kept at 37 ◦C, and removed at set time points. Zones of the agar were cut out, the agar sample
was put into ethanol (96%) and sonicated for 15 min. This extraction process was repeated twice and
the obtained ethanol solutions were combined. The vials with ethanol solutions were left under a fume
hood without caps, for the ethanol to evaporate. The residues left in the vials were dissolved in 1.5
mL of ethanol (96%) and the amount of CAM analyzed with HPLC. In the present study, the limit of
detection for CAM was 1 µg/mL. Triplicate measurements were performed. The extraction efficacy
was tested separately confirming that two times extraction resulted in 100% efficacy (Appendix A,
Table A1).
2.3.2. UV Imaging for Drug Release Monitoring in Hydrogel
Complementary to the traditional HPLC method, an Actipix D200 Large Area Imager (Paraytec
Ltd., York, England) controlled by Actipix D200 acquisition software ver. 3.1.7.4 was used to image the
release of CAM from PCL and PCL/PEO fiber mats. These experiments were performed in a heating
cabinet from Edmund Bühler TH30 (Bodelshausen, Germany) set to 37 ◦C. Imaging was performed at
four alternating wavelengths: 525 nm, 280 nm, 255 nm, and 214 nm. Images for each wavelength were
recorded at a frequency of 0.125 s−1 for the release experiments as well as the standard curve. The
imaging area (28 × 28 mm2; pixel size 13.8 µm2) encompassed three quartz cells (Pion Inc., UK; 62
mm × 4 mm × 7 mm (L × H × W)), allowing three measurements to be performed simultaneously.
The fibers were cut to fit the inner dimensions of the quartz cells (7.0 mm in width and 4.0 mm in
height). The fibers were positioned perpendicular to the imaging direction in contact with the agarose
gel. The fibers were backed by silicone plugs to ensure good contact with the gel and correct alignment.
Parafilm was used to seal the quartz cells preventing evaporation of water from the gels. The release of
CAM from the fibers was imaged for 3 h at 37 ◦C. Each imaging experiment allowed measurements of
two CAM-containing fibers and one blank fiber (control). The positioning of the fibers in the imaging
system (top, middle or bottom row) was randomized.
Standard Curve for quantification by UV imaging. A CAM stock solution (5 mM) in phosphate buffer
was used to make the dilutions for the standard curve in 0.5% (w/V) agarose gel. These were made
by mixing 1.5 mL 1% (w/V) agarose in phosphate buffer with a defined volume of CAM solution and
phosphate buffer to obtain 3 mL of the mixture. The 1% (w/V) agarose solution and the phosphate
buffer were both heated in water bath (98 ◦C) to facilitate mixing leading to a homogeneous mixture.
The gels were cast in the quartz cells, and allowed to settle for 30 min prior to the experiments. As
reference, a 0.5% (w/V) agarose gel in phosphate buffer without CAM was used.
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2.4. Antibacterial Activity Studies—Drug Release and Effect on Bacterial Growth
2.4.1. Antibacterial Activity Testing
The antibacterial activity of released CAM on agar plates was investigated at different time points
mimicking the drug diffusion tests into agarose hydrogel during UV imaging studies. Overnight
culture (20 h) of S. aureus DSM No.: 2569 was grown from DMSO stock (100 uL to 3 mL of LB).
Preparation of all bacterial DMSO stocks used in the present study is described in Appendix B. The
culture was diluted to optical density (OD) 0.05 in LB and 100 µL was plated onto pre-warmed LB agar
plates (1.5% (w/V)). PCL/CAM and PCL/PEO/CAM fiber discs, and a positive CAM filter paper control
were applied onto each plate. At specific time points, the discs were removed and the LB plates were
incubated at 37 ◦C for 24 h prior to measurement of the inhibition zones.
2.4.2. Bioreporter Plasmid and Strain Preparation
All cloning was performed using CPEC cloning method [40]. Plasmid vector backbone was
low-copy pSC101 plasmid. Timer reporter gene in plasmid pSC101-Ptet-Timer [41] was replaced with
two fluorescent reporter genes GFPmut2 [42] and mScarlet-I [43]. In order to increase the expression of
the green fluorescence protein (GFP) during antibiotic stress additional stress-inducible dnaK1 promoter
(PdnaK1) originating from E. coli MG1655 genomic DNA was added upstream of the tet-promoter
(Ptet). In addition, kanamycin resistance gene kanR was replaced with ampicillin resistance gene ampR.
In order to reduce the expression of ampR resulting from reverse direction transcription initiation from
PdnaK1, additional rrnB T2 terminator was added between ampR and PdnaK1.
In order to construct the ribosomal stalling reporter plasmid pSC101-CAM-bioreporter
transcription attenuation-based regulatory trpL2Ala region together with a terminator and constitutive
T5 promoter from plasmid, pRFPCER-TrpL2A [44] was inserted between GFPmut2 and mScarlet-I
ribosomal binding site. mRNA from the reporter gene mScarlet-I, and therefore, red fluorescence is
only produced when ribosomal stalling occurs, e.g., due to CAM presence (Appendix C).
CPEC products were transformed into E. coli DH5α and plasmids were purified using FavorPrep
Plasmid DNA Extraction Mini Kit. All plasmids were verified by sequencing. Purified bioreporter
plasmid pSC101-CAM-bioreporter was transformed into E. coli MG1655 chemical competent cells via
heat shock. The transformants were selected on ampicillin (100 µg/mL) containing LB-agar plates
after overnight incubation. The full nucleotide sequence of the pSC101-CAM-bioreporter plasmid is
provided as Supplementary Materials in GeneBank (gb) file format.
2.4.3. Bioreporter Disc Diffusion Assay
For bacterial bioreporter disc diffusion assay agar plates with defined MOPS minimal medium [39]
supplemented with 0.4% (w/V) glucose as the carbon source and 1.5% (w/V) agar were prepared in
sterile conditions by measuring 20 mL of warm agar medium per plate, and plates were dried for 30
min under laminar flow hood.
Bioreporter strain DMSO stock was thawed, diluted 20× into sterile 1× PBS and 75 µL was
plated on each minimal plate. A sterile cotton bud dipped into 1× PBS was used to spread the cells
evenly. Plates were left to incubate at 37 ◦C for 10 h. After incubation, the weighted fiber mats
(PCL/PEO/CAM and PCL/CAM) were added to each plate. Individual plates were first scanned with
the Amersham Typhoon scanner (GE Healthcare Europe GmbH, Freiburg, Germany) (pixel size 100
µm; green fluorescence: 488 nm laser, 525BP20 filter, PMT voltage 352V; red fluorescence: 532 nm laser,
570BP20 filter, PMT voltage 621V) after adding the mats and re-scanned every hour for 6 h. Scan time
for each plate was approximately 6 min. The plates were incubated at 37 ◦C between the scans.
2.5. Data Analysis
Data are given as average ± standard deviation (SD), unless stated otherwise. Data were analyzed
and figures plotted using MS Excel 2017 and/or 2016, GraphPad Prism 7 ver. 7.04 or OriginPro 8.5.
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Statistical analysis was performed by two-tailed Student’s t-test assuming unequal variances (p < 0.05)
where applicable.
The SDI Data analysis software ver. 2.0.60624 (Paraytec Ltd., York, England) was used to analyze
the recordings made on the Actipix D200 system. The CAM molar absorption coefficient determined
from the standard curve was used to calculate CAM concentrations in the gels. The analysis was
performed at 255 nm, because the linear range of the standard curve covered the absorbance values
encountered in the release experiments in contrast to 280 nm. A 6.25 mm wide zone starting from
the fiber-gel interface protruding into the gel in the CAM transport direction was defined. For each
pixel column, the absorbance was averaged, converted to concentration and plotted as a function of
distance from the fiber mat to attain concentration-distance profiles. From the concentration-distance
profiles, the area under curve (AUC) was calculated to determine the total amount of CAM released
from the fibers.
The inhibition zones free of bacterial growth (diameters, mm) were determined using ImageJ
software [45] program version 1.52n. Tests were run at least in triplicate. ImageJ software was also
used for obtaining numerical values of fluorescent zones from disc diffusion assay images. Green
and red fluorescence images were analyzed separately. 0.8 mm wide lines were chosen as regions of
interest for analysis. The 1.5 cm long line was drawn starting from the fiber mat and plot profiles of
grey values for these regions were recorded.
3. Results and Discussion
3.1. Preparation and Characterization of Electrospun Fiber Mats
In order to test the suitability of the UV imaging technique and different drug release model
systems for monitoring drug release from electrospun fiber mats, different mats were electrospun by
varying the polymers (hydrophilic PEO vs. hydrophobic PCL) and incorporating the antibacterial drug
CAM into the fibers (Table 1). The preparation and morphological and physicochemical characterization
of these electrospun antibacterial CAM-loaded fibers has been performed previously [22]. As shown
previously, the prepared PCL and PCL/CAM mats consisted of nanofibers within the average size
range from 370 to 496 nm (SD ± 339 nm), whereas PCL/PEO and PCL/PEO/CAM mats were in the
micrometer size range with an average diameter of 2.9 µm (SD ± 1.1 µm). Solid state transformation
from crystalline CAM to amorphous CAM was confirmed with drug-loaded electrospun fiber mats
(data not shown). In agreement with previous findings [22], CAM was homogeneously distributed
within the electrospun fiber mats (data not shown) and CAM content matched with the theoretical
values (Table 2).
Table 2. Average CAM concentrations within the electrospun fiber mats (N = 3–7). Formulation
compositions and electrospinning parameters are shown in Table 1.
Electrospun Fiber Formulations Theoretical CAM Content/% Measured CAM Content/% ± SD
PCL/CAM 4 4.0 ± 0.2
PCL/PEO/CAM 4 3.8 ± 0.3
Key: CAM, chloramphenicol; SD, standard deviation.
3.2. Drug Release into Buffer Measured by UV-VIS Spectrophotometry
Initially, traditional dissolution testing into buffer solution was performed and CAM concentrations
were determined using UV-VIS spectrophotometry. The PCL/CAM and PCL/PEO/CAM mats are
different in terms of their wettability and swelling properties. PCL/PEO/CAM mats are more hydrophilic
and swell when exposed to an aqueous medium [22]. The PCL/CAM mats are more hydrophobic,
although the presence of CAM tends to increase the wetting of the mat and provide access for the
buffer to enter the fibers. Thus, PCL/CAM fiber mats provided the expected and desired prolonged
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CAM release whilst PCL/PEO/CAM mats due to the hydrophilic nature of PEO exhibited a faster drug
release in buffer solution (Figure 1).
Figure 1. Relative release of CAM from PCL/PEO/CAM (n) and PCL/CAM () fiber mats into phosphate
buffered saline at pH 7.40 and 37 ◦C. Data are averages ± SD of at least triplicate samples. Analyses
performed using UV-VIS spectrophotometry (reference is made to Table 1 for fiber composition and
preparation conditions).
Frequent sampling revealed a significant CAM burst release (up to 15 min of release testing) from
both fiber mats. There were only minor differences in triplicate measurements and in the behavior
of the fiber mats verifying the reproducibility of the measurements. In a recent study, the free drug
(terbinafine hydrochloride) on the surface of fibers was removed after rinsing in distilled water and
the amount of released drug quantified in a wound dressing-skin model utilizing filter paper as a
matrix [21]. The rinsing procedure most likely removed the drug burst release. In the present study,
no pretreatment of the mats was performed and the mats were analyzed directly. It is likely that if
burst released amounts were removed the drug release would be even more different between the
mats and most of CAM would be removed from PCL/PEO/CAM fibers mats during the pretreatment.
For understanding drug release and in vivo activity relationships, the mats should not be pretreated;
however, such pretreatment might be important if in vitro tests are performed to illustrate only the
differences between the fiber mats in respect of their prolonged drug release.
3.3. Antibacterial Activity of Electrospun Fiber Mats
Despite the different morphologies and behavior (e.g., swelling, drug release into buffer),
statistically significant differences in the inhibition zones on agar plate between the PCL/CAM
and PCL/PEO/CAM fiber mats were not observed during previous antibacterial activity testing [22].
In the present study, it was of interest to investigate further how the drug is released from the
electrospun mat into a gel which more closely resembles the wound matrix (e.g., agar and agarose
hydrogels) and how this translates into antibacterial effect. Hydrogels have more similar hydrodynamic
conditions to wound tissue as compared to aqueous solutions and thus provide more biorelevant
testing option. We developed a modified disc diffusion assay, where the mats were physically removed
from the surface of the solid growth medium at specified time points and the antibacterial effect of
the released drug on model bacteria S. aureus DSM No.: 2569 was determined by measuring the size
of the inhibition zones after 24 h. The faster CAM release from PCL/PEO/CAM mats compared to
the PCL/CAM mats observed in buffer solution (Figure 1) correlated with larger inhibition zones
(Figure 2). The differences were larger at the earlier time points. Control filter paper impregnated with
CAM confirmed that the wetting of the sample is the major triggering factor for further drug release
and diffusion.
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Figure 2. Inhibition zone diameters measured after 24 h on agar plates. X-axis indicates exposure time
of discs (PCL/PEO/CAM or PCL/CAM fiber mats) onto the hydrogel. S. aureus DSM No.: 2569 was used
for the study. Filter paper wetted with CAM solution and dried (same CAM concentration) served as
a control. Key: CAM, chloramphenicol; PCL, polycaprolactone; PEO, polyethylene oxide. Data are
averages ± SD of at least triplicate samples.
3.4. Drug Release into Agar Hydrogel Measured by HPLC
The extent of CAM release from the mats and diffusion into the agar hydrogel was quantified
using HPLC upon extraction of CAM from the agar hydrogel. The agar on the plates was divided into
five concentric circular zones (Figure 3A) and the CAM concentration in each zone was determined.
The experimental design is detailed in the Materials and Methods and Appendix A (Tables A1 and A2).
The amount of drug released from electrospun mats to the agar plates at different time points at 37 ◦C
is summarized in Figure 3.
Figure 3. (A) Schematic illustrating the division of the agar plate into zones. Zones 1-5 are numbered
starting from the inner circle. Zone diameters: 1.0 cm, 3.0 cm, 4.4 cm, 5.8 cm, and 8.6 cm. Concentrations
of released CAM (detection limit of 1 µg/mL) from PCL/PEO/CAM (B) and PCL/CAM fiber mats (C)
into 1.5% (w/V) agar hydrogel at 37 ◦C in different time points (1 min, 30 min, 180 min) and into
different zones (1–4). Error bars represent standard deviation, N = 3. Key: CAM, chloramphenicol;
PCL, polycaprolactone; PEO, polyethylene oxide.
The drug diffusion patterns for PCL/CAM and PCL/PEO/CAM fiber mats were qualitatively
similar (Figure 3). These findings are consistent with the disc diffusion assay results (see for Figure 2).
It is clear that most of the drug is present in the 1 cm diameter section (zone 1) right below the fiber
mat at the early time points of the release experiment. As time passed, less drug was recovered in
the inner circle (zone 1) and relatively more in zone 2 (larger circle around the mat). CAM release
from PCL/PEO/CAM fiber mat was fast followed by slower diffusion further into the agar hydrogel
(Figure 3B). Interestingly, after 120 min, the drug was not detectable in the 3rd zone. After 24 h
(1440 min), the CAM had reached the outer circle (Appendix A, Table A2). PCL/CAM fiber mats on
the other hand showed that less drug was released within the same time period compared to the
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PCL/PEO/CAM fiber mat (Figure 3C). The CAM concentration distribution differences are visible in
Figure 3, mainly for zone 1 but to some extent also for zone 2. This may explain why it is not always
possible to detect differences in the inhibition zones between different fiber mats in a disc diffusion
assay although the drug may be released differently from the delivery vehicle and, therefore, lead to
different antibacterial efficacy in vivo [46].
3.5. Detecting CAM Release into Agar Hydrogel with Bioreporter Strain
In addition to chemical and physical methods for determining the CAM concentrations during the
release, it is also possible to use bacterial bioassays. Hence, simultaneously to the antibacterial effects,
the drug release can be monitored. We genetically engineered reporter bacteria (E. coli MG1655) to
produce dose-dependent quantifiable green and red fluorescent signals in the presence of antibacterial
drug CAM. The CAM-bioreporter has GFP as a control protein for expression and a red mScarlet-I as a
reporter protein. Exact working mechanism of the bacterial bioreporter is provided in Appendix C. In the
presence of CAM GFP signal (green) will be reduced due to protein synthesis inhibition, and mScarlet-I
signal (red) will increase due to transcription continuation as a result of ribosomal stalling in the
transcription attenuation system. Therefore, the CAM release and diffusion can be illustrated in different
time points (selected time points 60, 180, and 360 min) using fluorescence data (Figure 4).
Figure 4. (A,B). Shows the analyzed region of interest (0.8 mm × 1.5 cm) of bioreporter chloramphenicol
(CAM)-containing fiber disc diffusion assay from green fluorescence (A) and red fluorescence (B) scan
images. Green fluorescence images in different time points (60 min and 180 min) allow estimating
bacterial growth inhibition due to CAM released from PCL/PEO/CAM and PCL/CAM fiber mats (C).
Combined green and red fluorescent figures at 6 h reveal the fluorescence levels that can be correlated
with the released CAM from PCL/PEO/CAM (D) and PCL/CAM fiber mats (E). Data are presented
as average of three experiments (± SD). Key: CAM, chloramphenicol; PCL, polycaprolactone; PEO,
polyethylene oxide.
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It is clearly seen that bacterial growth is inhibited close to the fiber mats (inhibition zones
surrounding the mats) where CAM concentrations are the highest, which matches with the agar
diffusion test results (Figures 2 and 3). Fluorescent bacteria surrounding the inhibition zones reveal
the distance from the mat where the CAM levels above the minimum inhibitory concentration (MIC)
can still be detected. Compared to the agar hydrogel diffusion tests (Figures 2 and 3), bacterial
bioreporter study results on agar hydrogel did not reveal large differences between the PCL/CAM
and PCL/PEO/CAM fiber mats with the respect of released drug amounts and its effect on bacteria
(Figure 4C). Growth inhibition was very slightly more pronounced in PCL/PEO/CAM fiber mat (fast
release) after 60 min of incubation; however, this difference was statistically insignificant and disappears
in later time points (180 min). In later time points (6 h) red fluorescence detected from bacteria enabled
determining the CAM concentrations even below MIC (in sub-MIC concentrations) (Figure 4D,E).
After 6 h of incubation, the peak of the reporter protein signal is located further (approximately
0.75 cm) from the mat in case of PCL/PEO/CAM fiber mat (fast release) (Figure 4D) compared from
PCL/CAM fiber mat (slow release; located approximately 0.60 cm) (Figure 4E). This indicates that
effective CAM concentration was achieved on larger area (at a further distance from the fiber mat)
with PCL/PEO/CAM fiber mat, although the difference between the two fiber mats was minor. Most
likely, this is due to the fact that most of the differences between the two different electrospun fiber
mats can only be seen in early time points which cannot be distinguished using fluorescent bacteria in
these settings.
3.6. Drug Release into Agarose Hydrogel Using UV Imaging
The assessment of CAM release by cutting of zones from agar plates followed by extraction and
analysis of the drug is both a destructive and laborious sampling procedure. The fast release of CAM
cannot be monitored using bioreporter bacteria that require time for growth and detectable signal
production. Therefore, UV imaging was investigated as a potentially less labor intensive and more
robust (reproducible/repeatable) approach for monitoring CAM release from the electrospun fiber
mats. An additional benefit of the non-intrusive imaging method is the high spatial as well as temporal
resolution offered. Due to a lack of transparency of the agar plates used in antibacterial activity tests,
a hydrogel matrix based on agarose was applied instead. Moreover, the Actipix D200 Large Area
Imager allowed imaging of three samples in parallel enabling comparison. Images visualizing the
release and diffusion of CAM at different time points are shown in Figure 5A.
Diffusion into the viscous agarose hydrogel resembles the conditions encountered both during
in vitro disc diffusion testing (agar hydrogel) as well as in vivo where the drug has to be released from
the electrospun fiber and diffuse into the wound. The UV imaging results reveal that PCL/CAM
fibers provide slower drug release into the gel whereas PCL/PEO/CAM fibers release the drug faster
(Figure 5A). The concentration-distance profiles shown in Figure 5B,C correspond to the images in
Figure 5A. In addition, the average amount of CAM released was quantified based on the UV images
(Figure 6). When comparing the two mats, differences were observed with respect to the total amount
of released drug mainly at the early time points (Figure 6).
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Figure 5. (A) Representative images of CAM release from fibers and diffusion into 0.5% (w/V) agarose
hydrogel at 37 ◦C. Top is PCL/PEO/CAM, middle is PCL/CAM and bottom is PCL/Blank fibers (control).
The zone used for the quantification of the CAM absorbance is shown in the middle row at 30 min.
Representative concentration-distance profiles for PCL/PEO/CAM (B) and PCL/CAM (C) fibers diffusing
into 0.5% (w/V) agarose hydrogel at 37 ◦C. The red, black and blue line is for 0 min (immediately
after starting the experiment), 30 min and 180 min, respectively. Key: CAM, chloramphenicol; PCL,
polycaprolactone; PEO, polyethylene oxide.
Figure 6. Amount of CAM released from PCL/PEO/CAM (n) and PCL/CAM () fiber mats into 0.5%
(w/V) agarose hydrogel at 37 ◦C based on UV imaging experiment data. Error bars represent one standard
deviation, N = 5. Key: CAM, chloramphenicol; PCL, polycaprolactone; PEO, polyethylene oxide.
Only slight differences between the PCL/CAM and PCL/PEO/CAM fiber mats with respect to
their drug release behavior were detected in average drug release profiles, although these were not
statistically significant and can be considered as more of a tendency.
3.7. Comparison between Different Drug Release Model Systems
Irrespective of the in vitro release model system (testing approach) employed, the release of CAM
was found to be faster from the PCL/PEO fiber mats as compared to the PCL fiber mats (Figure 7).
However, the extent to which the release differed tended to vary between the model systems.
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Figure 7. Amount of CAM released from PCL/PEO/CAM and PCL/CAM fiber mats into phosphate
buffered saline at pH 7.40 and 37 ◦C and 1.5% (w/V) agar hydrogel at 37 ◦C and 0.5% (w/V) agarose
hydrogel at 37 ◦C. Data are averages ± SD of at least triplicate samples. Analyzes performed using
UV-VIS spectrophotometry (CAM concentration in a buffer solution), HPLC (CAM concentration
extracted from hydrogel) and UV imaging (CAM concentration within hydrogel) (reference is made
to Table 1 for fiber composition and preparation conditions). Key: CAM, chloramphenicol; PCL,
polycaprolactone; PEO, polyethylene oxide.
Drug release into buffer revealed that after 30 min the PCL/PEO/CAM fibers had released nearly
all CAM into the buffer, whereas only a minor amount (approximately 30%) of drug was released from
PCL/CAM fiber mats (Figure 7). When the CAM release into hydrogel was monitored by agar disc
diffusion and extraction method, the amount of CAM released from PCL/PEO/CAM fiber mat after
30 min was approximately 70% and the released CAM amount from PCL/CAM mat was similarly
approximately 30% (with huge variability between 17–48% for individual PCL/CAM fiber mats). UV
imaging, however, showed that the differences with respect to the amount of drug released into the
agarose hydrogel between PCL/CAM and PCL/PEO/CAM fiber mats after 30 min were less pronounced
as compared to the differences in CAM release into buffer (Figure 7). It was also seen that much less
CAM was released and diffused to the region of analysis from both fiber mats (approximately 9% and
8% for PCL/PEO/CAM and PCL/CAM fiber mats, respectively) within the same time period. Most
likely, less CAM is released from the fiber mats into the hydrogel according to the UV imaging due to
the different geometries of the setup. In the UV imaging setup, diffusion is limited to one direction
perpendicular to the mat, whereas diffusion in the agar setup may occur in three dimensions. The latter
will favor a relatively larger release of CAM. We believe that the concentration may be more likely
to build up at the interface in the UV imaging setup. As might be expected due to the similarity of
the release matrices (hydrogel), the UV imaging drug release and diffusion profiles matched more
with the drug release into agar hydrogel extraction (Figures 3–5) than release and dissolution into
buffer test (Figure 1). The contact and/or of the mats with the hydrogels may be different between
the agar and agarose hydrogels. It is not known whether the agar hydrogel may contain components
interacting, and thereby facilitating the release of CAM. Similarly to UV imaging, less pronounced
differences between the two different electrospun CAM-loaded fiber mats were also observed with
bacterial bioreporters (Figure 4C). It is due to the fact that the drug has to diffuse away from the
mat before it will be detected (UV imaging and bacterial bioreporters), whereas in the agar hydrogel
extraction method, the area under the fiber mat will be included into the total released and detected
drug amount.
The differences with respect to CAM release from the mats observed using the in vitro release
testing model systems are related to the different properties of the release media (volume, agitation, and
viscosity), its capability to penetrate into the fiber mat, the sample size of fiber mats, effect of shaking,
and geometry of the setup. It is believed that drug diffusion and wetting of the samples were the
rate-limiting steps for the drug release from fiber mat into agar and agarose hydrogels. The release into
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buffer solution, however, was more affected by the hydrodynamics of the buffer measurements. For
the different fiber mats agitation led to increased erosion and/or disintegration of the PCL/PEO/CAM
fiber mats as compared to the PCL/CAM fiber mats.
In terms of repeatability the model systems and analytical methods were all comparable. It can
be seen that larger variations in drug release between replicates were detected for PCL/CAM fiber
mats compared to PCL/PEO/CAM fiber mats. This was seen with both drug release model systems
(buffer vs. hydrogel) as well as different techniques (UV-VIS spectrophotometry, HPLC, UV imaging,
and bacterial bioreporters). This might be explained by the different wettability of the PCL/CAM
fiber mats compared to PCL/PEO/CAM fiber mats as discussed previously for PCL and PCL-drug
loaded fiber mats [15]. The hydrophilicity of the PCL/PEO/CAM fiber mats makes them wet more
homogeneously, whereas for PCL/CAM fiber mats the sample-to-sample variations in wettability may
also cause variability in the drug release behavior.
Compared to agar diffusion assay (extraction of CAM from hydrogel), the UV imaging was easier
to conduct. Although for both these methods the size of sample, the release environment (hydrogel) and
static conditions resembled the in vitro antibacterial activity testing conditions. Bacterial bioreporter
study enabled to monitor the CAM release into agar hydrogel during diffusion in later time points
where even sub-MIC concentration of CAM was determined based on the green and red fluorescence
intensity. The method has the advantage of revealing the released antibacterial drug effect directly
on bacteria.
For polymer fiber mats as wound matrices it is favorable to have the burst effect. The extent
of the burst release is often associated with device geometry, surface characteristics of host material,
heterogeneous distribution of drug within the polymer matrix, intrinsic dissolution rate of drug, and
heterogeneity of matrices [16]. From the drug release experiments we see that the burst release is
smaller with the hydrogels for hydrophilic PCL/PEO/CAM and hydrophobic PCL/CAM fiber mats
compared to the buffer solution (Figure 7). Larger differences in the burst release between the samples
were observed with hydrophobic PCL/CAM fiber mats (Figure 7). For the drug release to occur from
the PCL fiber mat, the medium needs to penetrate into the electrospun fiber mat to cause the diffusion
of the drug to the exterior. Initially, the diffusion is affected by the electrospun mat composition and
the fiber characteristics, as for PCL/PEO/CAM fiber mats the release was also affected by swelling
and dissolution of PEO. As a second step, the diffusion further into the wound and reaction with the
surrounding tissue and environment is important [47]. It is clear that the buffer release method shows
higher burst release as compared to the in vitro antibacterial activity testing. Sadri et al. have measured
tetracycline release in a dialysis bag mimicking the human skin-like conditions and shown that the
burst release effect is reduced most likely due to the diffusion through the bag, which modified the
release [48]. The gels in vitro and the wound tissue in vivo can be envisioned to provide a diffusion
barrier or matrix minimizing burst release effects. Local transport mechanisms determine the volume
in which the drug is distributed; thus, understanding these mechanisms is essential for optimizing the
effectiveness of local delivery [47]. The in vitro methods that enable to most closely mimic the in vivo
conditions are likely to enable accurate predictions of the drug release and transport in the wound
environment. Moreover, it is important to understand the effect on bacteria. Therefore, the response of
the bacteria to the active antibiotic concentration has to be measured directly. Here, we have shown
that genetically engineered bioreporter systems can be used for this purpose.
4. Summary and Conclusions
All tested drug release model systems enabled to study the drug release from electrospun fiber
mats. UV imaging provided faster, non-intrusive real-time information on chloramphenicol (CAM)
release and diffusion with higher spatial and temporal resolution as compared to the release methods
relying on release from fiber mats directly into buffer solution as well as to the agar plates followed by
destructive sampling. The data were similar in terms of sensitivity in detecting differences between
the electrospun fiber mat compositions in comparison to the more laborious drug release testing
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setups. Furthermore, the UV imaging and release into hydrogel method appeared to mimic the
in vitro antibacterial activity testing conditions to a large degree, while release into buffer solution
overestimated the burst release effects.
Advanced antibacterial disc diffusion assays enabled to distinguish small differences in the
antibacterial activity of the differently designed electrospun fiber mats, these slight differences were
also visualized using UV imaging as well as modified drug release and diffusion into hydrogel model
systems. These results suggest that diffusional resistance to drug release observed in the hydrogel
based systems may emulate the in vivo conditions of the wound matrix.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/9/487/s1.
The full nucleotide sequence of the pSC101-CAM-bioreporter plasmid is provided in GeneBank (gb) file format.
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Appendix A. Drug Release Into Agar Hydrogel
Table A1. Confirmation of extraction efficacy.
mg/Samples % Extracted
0.119 66.6% E1 1x extraction
0.122 68.2% E2
0.119 66.6% E3
67.1%
0.186 103.9% E1 2x extraction
0.191 106.8% E2
0.177 98.9% E3
103.2%
Two times extraction used in the present study provides approximately 100% efficacy.
Table A2. Percentage of total amount of drug CAM recovered from all sections on the agar plate.
The release of CAM into agar hydrogel was monitored from PCL/PEO/CAM fiber mats.
Zone 5 min 10 min 15 min 30 min 60 min 120 min 1440 min
1 86.8 80.6 78.1 88.5 66.6 62.6 11.8
2 13.2 19.4 21.9 11.5 33.4 37.4 54.6
3 0.0 0.0 0.0 0.0 0.0 0.0 26.9
4 0.0 0.0 0.0 0.0 0.0 0.0 6.3
5 0.0 0.0 0.0 0.0 0.0 0.0 0.4
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Appendix B
DMSO stocks preparation. Overnight culture was diluted 100 times into fresh LB medium (100 µL
on bacteria in 10 mL medium) and grown aerobically at 37 ◦C to an OD of 0.8–1 (OD600), cultures
were chilled on ice and dimethylsulfoxide (DMSO) was added to a final concentration of 8%. 120 µL of
suspension was added to PCR tubes and frozen in liquid nitrogen. The tubes were stored at −80 ◦C
and used within 6 months.
Appendix C
Bacterial bioreporters. Bacterial bioreporters are genetically engineered cells, which will produce
a measurable signal in response to some chemical or physical environmental change [36]. In the
present study, bacteria were developed to report the presence of antibacterial drug CAM by producing
fluorescent proteins. Schematics explaining the working principle of bacterial bioreporters are provided
in Figure A1.
Our developed CAM-bioreporter has GFP as a control protein for expression and a red mScarlet-I
as a reporter protein. When there is no CAM present, only GFP (green) signal is produced by bacteria
(Figure A2).
Bacteria exhibit fast translation and green protein production. In the presence of CAM GFP signal
(green) will be reduced due to protein synthesis inhibition, and reporter protein mScarlet-I signal (red)
will increase due to transcription continuation as a result of ribosomal stalling in the transcription
attenuation system.
Figure A1. Schematics about bacterial bioreporter system working principle. Key: CAM—
chloramphenicol; GFP—green fluorescent protein; mRNA—messenger RNA; 30S/50S—ribosomal
subunits; RNA pol—RNA polymerase; PdnaK1 and Ptet—transcription promoters.
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Figure A2. Simplified schematics about bacterial bioreporter system working principle.
Key: CAM—chloramphenicol.
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